Skip to content

Trial Summary

This is an open-label, multicenter, extension study to evaluate the long-term safety of tislelizumab or pamiparib given either as monotherapy or in combination with each other or with other agents in participants with advanced malignancies who participated in a prior BeiGene sponsored clinical study (parent study).

Acronym:

BGB-A317-290

ACTRN/NCT /ethics:

NCT04164199

Scientific title:

An Open-Label, Multicentre, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients with Advanced Malignancies

Sponsor / Cooperative group:

Beigene

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2019-01-19
Anticipated End Date2024-12-16

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Amanda Townsend
Recruitment StatusRecruiting